---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-296619"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2022-12-01T23:59:59+00:00"
generated_at: "2026-06-21T11:06:01.183511+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma records $273.6M impairment on gantenerumab royalty after Roche halts trials

## Summary
- Non-cash impairment charge of $273.6M related to gantenerumab financial royalty asset.
- Roche discontinued gantenerumab trials Nov 30, 2022 after GRADUATE I/II missed primary endpoint.
- Impairment reflects entire net carrying value as of Sept 30, 2022; no impact on non-GAAP results.
- No portion of the charge relates to future cash expenditures.
- Charge will be recorded in Q4 2022 under GAAP.

## SEC filing metadata
- accession: 0001193125-22-296619
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2022-12-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.06
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000119312522296619/0001193125-22-296619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000119312522296619/d432184d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-296619
- JSON: https://secwatch.observer/filing/0001193125-22-296619.json
- Plain text: https://secwatch.observer/filing/0001193125-22-296619.txt

## Key facts
- Restructurings & Charges
  Royalty Pharma plc announced a impairment with charges of $273.6 million affecting financial royalty asset associated with gantenerumab.
  - Type: impairment
  - Charge: $273.6 million
  - Affected area: financial royalty asset associated with gantenerumab
  source text: endpoint of slowing clinical decline, which led the Company to conclude its financial royalty asset is impaired. The Company expects that the non-cash impairment charge will be $273.6 million, which was the net carrying value of the asset as of September 30, 2022. No portion of the impairment charge relates to future cash expenditures. SIGNATURES Pursuant to the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802768/000119312522296619/0001193125-22-296619-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.